The Halneuron Phase 2b readout in fall 2026 is the only meaningful catalyst — success could be transformative for this $62M market cap stock, but failure or delay would likely exhaust cash runway.
Price Chart
Executive Summary
Dogwood Therapeutics reported Q2 2026 net loss of $11.5M ($0.34/share) vs $3.8M ($1.99/share) in Q2 2025, driven by a $9.2M non-cash IPR&D impairment charge. Cash burn accelerated to $3.2M R&D spend, with cash runway of $9.6M now only through Q4 2026. The Halneuron Phase 2b readout remains the sole binary catalyst, but the widening loss, impairment, and shortened runway are clear negatives for a pre-revenue biotech with no approved products.
Key Financial Metrics
Key Facts
- Net loss attributable to common stockholders was $11.5M ($0.34/share) in Q2 2026 vs $3.8M ($1.99/share) in Q2 2025
- Recorded a $9.2M non-cash IPR&D impairment charge due to stock price decline triggering impairment testing
- Cash and cash equivalents fell to $9.6M from $13.2M at Q1 2026 end, providing runway only through Q4 2026
- Halneuron Phase 2b CINP trial enrolled 217 patients; top-line results expected fall 2026
- SP16 IND approved; Phase 1b CIPPN trial fully funded by NCI, enrolling in H2 2026
- Appointed Iain Dukes (OrbiMed Venture Partner) as Chair of Scientific Advisory Board
Financial Impact
Net loss widened to $11.5M from $3.8M YoY; $9.2M non-cash impairment; cash burn of $3.2M R&D + $1.6M G&A per quarter
Risk Factors
- Halneuron Phase 2b failure would likely render the stock worthless given no approved products and limited cash runway
- Cash runway only through Q4 2026 — dilutive financing likely needed before or after Phase 2b readout
- IPR&D impairment signals management's own assessment of diminished asset value
- No revenue and widening losses with no path to profitability without successful clinical data
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-095512 |
| Document: dwtx-20260813x8k.htm | 0001104659-26-095512 |
| Document: 0001104659-26-095512-index-headers.html | 0001104659-26-095512 |
| Document: 0001104659-26-095512-index.html | 0001104659-26-095512 |
| Document: 0001104659-26-095512.txt | 0001104659-26-095512 |
| 8-K Data (Synthetic) | 0001104659-26-095512 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 4d ago | SC 13D/A | $1.12 | awaiting T+60 | — | $1.12 (+0.16%) |
Oct 19, 2026 7d ago | 8-K | $1.21 | awaiting T+60 | — | $1.12 (−7.29%) |
Oct 19, 2026 7d ago | Press Release | $1.21 | awaiting T+60 | — | $1.12 (−7.29%) |
Aug 13, 2026 10w ago | 8-K | $1.98 | awaiting T+60 | — | $1.12 (+43.34%) |
May 18, 2026 23w ago | Press Release | $1.70 $1.93 | ▲ +13.24% | ▲ +8.38% | $1.12 (−34.01%) |
May 14, 2026 23w ago | 8-K | $1.98 $1.83 | ▼ −7.58% | ▼ −11.16% | $1.12 (−43.34%) |
May 14, 2026 23w ago | Press Release | $1.98 $1.83 | ▼ −7.58% | ▼ −11.16% | $1.12 (−43.34%) |
Apr 15, 2026 27w ago | Press Release | $1.71 $1.42 | ▼ −16.96% | ▼ −25.10% | $1.12 (−34.40%) |
Mar 18, 2026 31w ago | Press Release | $2.97 $1.57 | ▼ −47.14% | ▼ −58.66% | $1.12 (−62.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers